Latest News

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.

Florida ADAP cuts eligibility from 400% to 130% FPL, threatening 16,000 PLWHA.

Proposed $767M HIV cuts betray bipartisan legacy; RWHAP and PEPFAR face critical funding threats.

OIG report: 27% of Medicaid HIV enrollees lack evidence of critical services; state disparities exposed.

House appropriations proposes deep cuts to HIV/HCV funding including elimination of EHE initiative.

Tennessee rejects $8.3M in federal HIV prevention funding, threatening surveillance and care programs.

S.4395 would divert Ryan White resources from PLWHA to PrEP, threatening the safety net for vulnerable populations.

White House releases federal implementation plan with 380+ action items for National HIV/AIDS Strategy.

West Virginia's fragmented HIV services across four entities creates barriers; centralization needed.

CANN roundtable examines COVID-19 impacts on public health advocacy, Medicaid expansion, and HIV programs.

Medication abandonment disproportionately affects Black patients; PrEP users 41% more likely to abandon.

Post-PHE planning for Medicaid redetermination: extended timelines and navigator support for safety net care.

Family courts and child welfare systems miss opportunities to address health needs and social determinants.

Evaluates pandemic's impacts on HIV, HCV, and SUD services including testing disruptions and telehealth expansion.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.